Skip to main content
. 2019 Feb 5;38(2):176–183. doi: 10.1089/dna.2018.4462

FIG. 2.

FIG. 2.

LINC00460 accelerates the gefitinib chemotherapy resistance, invasion, and tumor growth in NSCLC cells. (A) RT-PCR revealed the LINC00460 expression in NSCLC cells (A549) administered with increasing concentration of gefitinib. (B) A549 cells were transfected with LINC00460 oligonucleotides, and gefitinib-resistant A549 cells (A549/GR) were transfected with LINC00460 plasmids. (C, D) Chemotherapy-sensitive test by CCK-8 revealed the IC50 value for gefitinib in A549 cells and A549/GR cells. (E) Transwell assays revealed the invasive cell count in A549 cells and A549/GR cells. (F) Multidrug-resistant-related protein (P-gp, MRP1, and BCRP) expression levels were measured using RT-PCR in A549 cells and A549/GR cells. (G, H) Xenograft mice in vivo assay showed the tumor volume and weight in the mice injected with A549 cells. Data are expressed as mean ± SD. *p < 0.05, **p < 0.01 represents statistical difference. CCK-8, cell counting kit-8; IC50, 50% maximal inhibitory concentration.